Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2025 Rev YoY: N/A EPS YoY: +8.9% Move: +11.83%

Replimune Group Inc

REPL

$7.75 11.83%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q4 2025

Published: May 22, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for REPL

Reported

Report Date

May 22, 2025

Quarter Q4 2025

Revenue

N/A

YoY: N/A

EPS

-0.82

YoY: +8.9%

Market Move

+11.83%

Previous quarter: Q3 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

EPS of $-0.82 increased by 8.9% from previous year
Net income of -74.13M
""data from the Ignite Study shows that roughly one-third of patients are able to achieve durable response in a high unmet need setting with few options."" - Sushil Patel

REPL

Company REPL

Period Q4 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

Replimune reported a materially negative quarterly and annual bottom line in Q4 2025 as the company advances RP1 toward potential FDA approval for anti-PD-1 failed melanoma. The BLA was acknowledged by the FDA in early 2025 with priority designation and a PDUFA target date of July 22, 2025, underscoring a pivotal inflection point for commercialization. Ignite 3, the confirmatory trial with overall survival as the primary endpoint, is underway and enrollment in the U.S. is on track with more than 100 sites planned globally, signaling a robust pathway to a potential launch upon approval. The company presented a clear strategic plan to commercialize RP1, including a U.S. manufacturing facility capable of supporting initial demand and long-term supply, a dedicated 60-person commercial organization, and a novel interventional radiology coordination framework to enable image-guided intra-tumoral injections.

Key Performance Indicators

Operating Income

Decreasing

-79.33M

QoQ: -20.15% | YoY: -35.01%

Net Income

Decreasing

-74.13M

QoQ: -11.74% | YoY: -34.60%

EPS

Increasing

-0.82

QoQ: -3.80% | YoY: 8.89%

Revenue Trend

Margin Analysis

Financial Highlights

- Profitability: Q4 2025 net income of -$74.1M; FY2025 net loss of -$247.3M; EPS (diluted) -$0.82 for Q4 2025. YoY metrics show gross profit decline and higher operating costs as R&D and SG&A scale for commercialization.
- Revenue and gross profit: Revenue not reported for Q4 2025; Q4 2025 gross profit of $0.736M on cost of revenue of -$0.736M, with gross profit YoY down ~-78.3% based on quarterly comparison.
- Expenses: R&D expense surged to $55.0M in Q4 2025 and $189.4M for FY2025; SG&A was $24.3M in Q4 2025 and $72.2M for FY2025. Stock-based compensation contributed $4.5M in Q4 2025 and $18.4M in FY2025 R&D; SG&A included $3.8M and $16.6M in SBC, respectively.
- Cash and liquidity: Ended FY2025 with $483.8M in cash and equivalents; management contends existing liquidity can fund operations into Q4 2026, supporting RP1 commercialization readiness.
- Milestones and guidance: PDUFA date set for July 22, 2025; Ignite 3 confirmatory trial ongoing with broad site expansion plans; management anticipates providing patient-based and payer metrics rather than revenue guidance during the early commercialization window.

Income Statement

Metric	Value	YoY Change	QoQ Change
Gross Profit	736.00K	-78.27%	N/A
Operating Income	-79.33M	-35.01%	-20.15%
Net Income	-74.13M	-34.60%	-11.74%
EPS	-0.82	8.89%	-3.80%

Key Financial Ratios

Return on Assets

Weak

-0.13%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.18%

Return on equity suggests inefficient capital allocation

P/E Ratio

Negative

-2.65x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.89x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	EPS ($)	YoY Growth	Report
Q1 2026	-0.95	+0.0%	View
Q4 2025	-0.82	+0.0%	View
Q3 2025	-0.79	+0.0%	View
Q2 2025	-0.68	+0.0%	View
Q1 2025	-0.78	+0.0%	View

REPL

Replimune Group Inc

Q1 2026 Report

Replimune Group Inc (REPL) QQ1 2026 Results — Oncolytic Immunogene Therapy Focus Amid Heavy R&D Spend and Robust Liquidity...

Read full report

REPL

Replimune Group Inc

Q3 2025 Report

Replimune Group Inc (REPL) QQ3 2025 Earnings Analysis — Oncolytic Immunotherapy Leader with Robust Liquidity but Extended Path to Profitability...

Read full report

REPL

Replimune Group Inc

Q2 2025 Report

Replimune Group Inc (REPL) QQ2 2025 Results – Oncolytic Immunotherapy Platform Progress and Deepening Cash Burn Ahead of Key Clinical Milestones...

Read full report

REPL

Replimune Group Inc

Q1 2025 Report

Replimune Group Inc (REPL) QQ1 2025 Earnings Analysis: Heavy R&D burn with no revenue, strong liquidity position, and an upcoming RP1-driven value pro...

Read full report

Replimune Group Inc (REPL) Q4 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More REPL Quarterly Reports

REPL

REPL

REPL

REPL

Q4 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

REPL Full Profile

REPL Financial Statements

Earnings Calendar